Please login to the form below

Not currently logged in
Email:
Password:

London Genetics senior appointments

London Genetics has made three appointments to its board and management team

London Genetics, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of genetics research, has made three appointments to its board and management team.

Dr Barrie Ward has been appointed as chairman to drive the next phase of the company's growth as the importance of pharmacogenetics in drug development increases. He previously held senior positions at GSK R&D and various biotechnology companies in the US and UK.

In addition, Dominique Kleyn has been brought on as CEO and Dr Mark Caulfield has been appointed clinical director. Kleyn previously held leadership roles at Imperial College London and within the biotech sector; Caulfield is an expert in the genetics of cardiovascular disease, particularly hypertension. He is director of the William Harvey Research Institute at Bart's and the London School of Medicine and Dentistry at Queen Mary, University of London.

Commenting on his appointment, Dr Ward said: "I am delighted to have joined the strong team at London Genetics at a time when the importance of pharmacogenetics in drug development is becoming increasingly clear. This is a pivotal phase of the company's development as it works in partnership with biopharmaceutical companies to add value to drug development programmes."

Ms Kleyn added: "We have an exciting partnering programme lined up for the coming months and I look forward to working together with our founding institutions and the biopharmaceutical industry to build interactions that will help to make a difference to drug development."

London Genetics has broad therapeutic experience with a particular focus on cardiovascular drugs and cardiovascular safety.

22nd September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics